Collaboration to include future projects developing novel tools for cancer screening and detection that leverage premier academic institution’s large set of diverse cancer samples
, /PRNewswire/ — Harbinger Health (“Harbinger,” “the Company”), a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, today announced a new collaboration with Memorial Sloan Kettering Cancer Center (“MSK”), one of the world’s largest leading cancer centers, to advance the Company’s blood-based early cancer detection platform.
In the near-term, Harbinger will leverage MSK’s expertise as a premier cancer center and academic institution to validate the Company’s assay from its Cancer Origin Epigenetics-Harbinger Health (CORE-HH, NCT05435066) prospective clinical study and advance its mission of developing an affordable, accessible and clinically informative test. This parallel study will complement Harbinger’s ongoing work with the Sarah Cannon Research Institute and will focus on a large sample of cancers. Luke R.G. Pike, M.D., D.Phil., Director of Brain Radiation Oncology at MSK, and MCED Lead …